Paradoxical enhancement of tumor growth in mice with severe combined immunodeficiency which produce a human immunoglobulin G reactive against tumor cells
- PMID: 8106291
- PMCID: PMC5919332
- DOI: 10.1111/j.1349-7006.1994.tb02888.x
Paradoxical enhancement of tumor growth in mice with severe combined immunodeficiency which produce a human immunoglobulin G reactive against tumor cells
Abstract
Mice with severe combined immunodeficiency reconstituted with human splenic tissue (SCID-sp) taken from 22 patients with advanced gastric cancer and 8 with idiopathic thrombocytopenic purpura (ITP) received subsequent implants of COLO 205 human colon cancer cells. A human immunoglobulin G (IgG) reactive against COLO 205 cells (COLO 205-reactive human IgG) was produced by SCID-sp mice reconstituted with splenic tissue from 8 of the 22 gastric cancer patients, but from none of the ITP patients. Tumor growth in SCID-sp mice which produced the COLO 205-reactive human IgG was greater (tumor weight range, 106-143%) than that in the control SCID mice, while that in SCID-sp mice reconstituted with splenic tissue from 8 ITP patients and that in SCID-sp mice reconstituted with splenic tissue from the other 14 gastric cancer patients which did not produce the COLO 205-reactive IgG were considerably lower and slightly lower, respectively, than those in the control SCID mice (tumor weight range, 56.7-108% and 79.4-119%, respectively). When the COLO 205-reactive human IgG titers in the sera of the SCID-sp mice, expressed as a ratio of the titers in the corresponding patient's serum, were plotted against the tumor weight in each SCID-sp mouse, significant correlations were observed in those that received splenic tissues from 6 of the 8 patients in which the COLO 205-reactive human IgG was produced. Furthermore, the tumor growth rates increased in proportion to the increased COLO 205-reactive human IgG titers in SCID-sp mice. Therefore, the SCID-sp model should be useful to study the paradoxical tumor growth possibly due to impaired immune reaction in patients with advanced gastric cancer.
References
-
- ) Bosma , G. C. , Custer , R. P. and Bosma , M. J.A severe combined immunodeficiency mutation in the mouse . Nature , 301 , 527 – 530 ( 1983. ). - PubMed
-
- ) McCune , J. M. , Namikawa , R. , Kaneshima , H. , Shultz , L. D. , Lieberman , M. and Weissman , I. L.The SCID‐hu mouse: murine model for the analysis of human hemato‐lymphoid differentiation and function . Science , 241 , 1632 – 1639 ( 1988. ). - PubMed
-
- ) Mosier , D. E. , Gulizia , R. J. , Baird , S. M. and Wilson , D. B.Transfer of a functional human immune system to mice with severe combined immunodeficiency . Nature , 335 , 256 – 259 ( 1988. ). - PubMed
-
- ) Duchosal , M. A. , Eming , S. A. , Fischer , P. , Leturcq , D. , BarbasIII , C. F. , McConahey , P. J. , Caothien , R. H. , Thornton , G. B. , Dixon , F. J. and Burton , D. R.Immunization of hu‐PBL‐SCID mice and the rescue of human monoclonal Fab fragments through combinatorial libraries . Nature , 355 , 258 – 262 ( 1992. ). - PubMed
-
- ) Kubota , T. , Yamaguchi , H. , Watanabe , M. , Yamamoto , T. , Takahara , T. , Takeuchi , T. , Furukawa , T. , Kase , S. , Kodaira , S. , Ishibiki , K. and Kitajima , M.High human IgG levels in severe combined immunodencient mouse reconstituted with human splenic tissues from patients with gastric cancer . Jpn. J. Cancer Res. , 83 , 300 – 303 ( 1992. ). - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical